Journal of Community Health

, Volume 40, Issue 1, pp 34–40 | Cite as

Awareness and Coverage of Mass Drug Administration for Elimination of Lymphatic Filariasis: A Community Based Cross Sectional Study in Nepal

  • Ram Kumar AdhikariEmail author
  • Jeevan Bahadur Sherchand
  • Shiva Raj Mishra
  • Kamal Ranabhat
  • Rajendra Raj Wagle
Original Paper


Lymphatic filariasis (LF) is among the major public health problems in Nepal. The disease is a major cause of morbidities primarily, lymphedema of legs and hydrocele and it impedes socio economic development in many endemic areas of the country. This study is aimed at exploring the understanding of people about mass drug administration (MDA) of the said disease and the status of compliance of MDA in Nepal. This study is a cross sectional study carried out among 894 household samples in three of the sixty LF endemic districts. The selected districts were Dhading, Kapilvastu and Kailali. The sentinel surveillance of sites in three districts constituted the sampling frame at the first stage. The peripheral health care centers in the sentinel sites constituted the sampling frame at the second stage of sampling. The coverage of MDA was 95.5 %. However, the compliance was less. Only 71.6 % of the respondents who took the drugs from health workers swallowed the diethyl carbamazine (DEC) completely, other did not swallow. In the present study, majority of respondents reported that they had heard or seen persons with side effects of DEC in their community. A total of 20 % of respondents reported that they had side effects after having DEC and only 3.9 % of these side effects were treated. The Female Community Health volunteers (FCHVs), health workers and radio/Television (TV) were the chief sources of MDA related information. This study recommends for a concerted public health action combining effective drug delivery mechanism and sound public awareness campaigns. The community people need to be made aware beforehand about the location, time of drug distribution. Also public awareness of the DEC should be conducted so that people would trust it and comply with the drug regime. Along with the health workers and radio/TV that has been used traditionally, we recommend mobilization of FCHVs in the public awareness campaigns the MDA campaigns.


Filariasis Awareness Lymphatic filariasis Elimination Mass drug administration Cross sectional studies Nepal 



We would like to thank Department of Community Medicine and Public Health for their support in carrying out this study. We are particularly indebted to Tulsi Adhikari; Epidemiological and Disease Control Division, District Health Office; Dang; Kapilbastu; Kailaili and all the participants of this study.

Conflict of interests



  1. 1.
    World Health Organization. (2006). Informal consultation on preventing disability from lymphatic filariasis, WHO, Geneva, August 2006. Weekly Epidemiology Records, 81(40), 373–384.Google Scholar
  2. 2.
    Department of Health Services (DoHS) MoHaP, Government of Nepal. (2011). Annual Report In Disease control; lymphatic filariasis, Kathmandu Department of Health Services 2011/12.Google Scholar
  3. 3.
    Sherchand, J. B., Obsomer, V., Thakur, G. D., & Hommel, M. (2003). Mapping of lymphatic filariasis in Nepal. Filaria Journal, 2(1), 7.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Central Bureau of Statistics. (2011). Area and population. In Number of households, populations by sex and density for municipalities, 2011 (pp. 16–17). Kathmandu (Nepal): Central Bereau of Statistics, Government of Nepal.Google Scholar
  5. 5.
    Talbot, J. T., Viall, A., Direny, A., de Rochars, M. B., Addiss, D., Streit, T., et al. (2008). Predictors of compliance in mass drug administration for the treatment and prevention of lymphatic filariasis in Leogane, Haiti. The American Journal of Tropical Medicine and Hygiene, 78(2), 283–288.Google Scholar
  6. 6.
    Ottesen, E., Duke, B., Karam, M., & Behbehani, K. (1997). Strategies and tools for the control/elimination of lymphatic filariasis. Bulletin of the World Health Organization, 75(6), 491.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Roy, R. N., Sarkar, A. P., Misra, R., Chakroborty, A., Mondal, T. K., & Bag, K. (2013). Coverage and awareness of and compliance with mass drug administration for elimination of lymphatic filariasis in Burdwan District West Bengal India. Journal of Health Population and Nutrition (JHPN), 31(2), 171–177.Google Scholar
  8. 8.
    Oqueka, T., Supali, T., Ismid, I. S., Rückert, P., Bradley, M., & Fischer, P. (2005). Impact of two rounds of mass drug administration using diethylcarbamazine combined with albendazole on the prevalence of Brugia timori and of intestinal helminths on Alor Island, Indonesia. Filaria Journal, 4(1), 5.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    de Rochars, M. B., Direny, A. N., Roberts, J. M., Addiss, D. G., Radday, J., Beach, M. J., et al. (2004). Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs. The American Journal of Tropical Medicine and Hygiene, 71(4), 466–470.PubMedGoogle Scholar
  10. 10.
    Ottesen, E. A., Vijayasekaran, V., Kumaraswami, V., Pillai, S. P., Sadanandam, A., Frederick, S., et al. (1990). A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis. New England Journal of Medicine, 322(16), 1113–1117.PubMedCrossRefGoogle Scholar
  11. 11.
    Ismail, M., Jayakody, R., Weil, G., Nirmalan, N., Jayasinghe, K., Abeyewickrema, W., et al. (1998). Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 92(1), 94–97.PubMedCrossRefGoogle Scholar
  12. 12.
    Taylor, M., Bandi, C., Hoerauf, A., & Lazdins, J. (2000). Wolbachia Bacteria of Filarial Nematodes: A target for control? Parasitology Today, 16(5), 179–180.PubMedCrossRefGoogle Scholar
  13. 13.
    Ismail, M., Jayakody, R., Weil, G., Fernando, D., De Silva, M., De Silva, G., et al. (2001). Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 95(3), 332–335.PubMedCrossRefGoogle Scholar
  14. 14.
    Babu, B. V., & Kar, S. K. (2004). Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Medicine and International Health TM & IH, 9(6), 702–709.CrossRefGoogle Scholar
  15. 15.
    National Health Education Information Communication Centre (NHEICC). (2004). Health education, information and communication (HEIC) program in Nepal. NHEICC: Kathmandu.Google Scholar
  16. 16.
    Glenton, C., Scheel, I. B., Pradhan, S., Lewin, S., Hodgins, S., & Shrestha, V. (2010). The female community health volunteer programme in Nepal: Decision makers’ perceptions of volunteerism, payment and other incentives. Social Science and Medicine, 70(12), 1920–1927.PubMedCrossRefGoogle Scholar
  17. 17.
    Malla, D. S., Giri, K., Karki, C., & Chaudhary, P. (2011). Achieving millennium development goals 4 and 5 in Nepal. BJOG An International Journal of Obstetrics and Gynaecology, 118(Suppl 2), 60–68.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Ram Kumar Adhikari
    • 1
    Email author
  • Jeevan Bahadur Sherchand
    • 1
  • Shiva Raj Mishra
    • 2
  • Kamal Ranabhat
    • 3
  • Rajendra Raj Wagle
    • 1
  1. 1.Institute of MedicineMaharajgunj Medical CampusKathmanduNepal
  2. 2.Manamohan Memorial Institute of Health SciencesLalitpurNepal
  3. 3.National Public Health LaboratoryKathmanduNepal

Personalised recommendations